型及花 计算机 2026 年 03 月 02 日 版及 行业系 相关研究 证券分析师 刘洋 A0230513050006 liuyang2@swsresearch.com 陈晴华 A0230525100001 chenqh@swsresearch.com 任梦妮 A0230521100005 renmn@swsresearch.com 林起贤 A0230519060002 linqx@swsresearch.com 黄忠煌 A0230519110001 huangzh@swsresearch.com 洪依真 A0230519060003 hongyz@swsresearch.com 杨海晏 A0230518070003 yanghy@swsresearch.com 李国盛 A0230521080003 ligs@swsresearch.com 张静含 A0230522080004 zhanqjh@swsresearch.com 马天一 A0230525040004 maty@swsresearch.com 曾子栋 A0230525070007 zengzd@swsresearch.com 李冲 A023052 ...

上述被担保人非上市公司关联人。 | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2026-017 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于上月为子公司担保的进展情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 资产负债率为 | 70%以上的全资及控股子公司 | | | | | --- | --- | --- | --- | --- | | 担保对 | 被担保人名称 | | 杭州润达医疗管理有限公司 | | | | 本次担保金额 5,758 | 万元 | | | | 象一 | 实际为其提供的担保余额 | 159,106.29 | 万元 | | | | 是否在前期预计额度内 是 | | □否 | □不适用：_________ | | | 本次担保是否有反担保 □是 | | 否 | □不适用：_________ | | 担保对 | 被担保人名称 | | | 上海润 ...

行 业 及 产 业 计算机 2026 年 03 月 02 日 行 业 研 究 / 行 业 深 度 相关研究 - 证券分析师 刘洋 A0230513050006 liuyang2@swsresearch.com 陈晴华 A0230525100001 chenqh@swsresearch.com 任梦妮 A0230521100005 renmn@swsresearch.com 林起贤 A0230519060002 linqx@swsresearch.com 黄忠煌 A0230519110001 huangzh@swsresearch.com 洪依真 A0230519060003 hongyz@swsresearch.com 杨海晏 A0230518070003 yanghy@swsresearch.com 李国盛 A0230521080003 ligs@swsresearch.com 张静含 A0230522080004 zhangjh@swsresearch.com 马天一 A0230525040004 maty@swsresearch.com 曾子栋 A0230525070007 zengzd@swsrese ...

2月25日，润达医疗涨3.79%，成交额7.00亿元。两融数据显示，当日润达医疗获融资买入额6707.20万 元，融资偿还5899.94万元，融资净买入807.26万元。截至2月25日，润达医疗融资融券余额合计6.29亿 元。 融资方面，润达医疗当日融资买入6707.20万元。当前融资余额6.26亿元，占流通市值的6.31%，融资余 额超过近一年50%分位水平，处于较高位。 融券方面，润达医疗2月25日融券偿还0.00股，融券卖出4.43万股，按当日收盘价计算，卖出金额72.83 万元；融券余量16.27万股，融券余额267.48万元，超过近一年90%分位水平，处于高位。 资料显示，上海润达医疗科技股份有限公司位于上海市虹口区乍浦路89号星荟中心1座8楼，成立日期 1999年1月6日，上市日期2015年5月27日，公司主营业务涉及通过自有综合服务体系向各类医学实验室 提供体外诊断产品及专业技术支持的综合服务。主营业务收入构成为：试剂及其他耗材93.50%，仪器 3.70%，软件开发及服务2.67%，其他(补充)0.14%。 截至9月30日，润达医疗股东户数6.48万，较上期减少1.05%；人均流通股9317股 ...

证券研究报告 把握AI主线，重视新科技 ——计算机行业2026春季投资策略 行业投资评级：强于大市|维持 孙业亮/刘聪颖 中邮证券研究所 计算机团队 中邮证券 1 1 发布时间：2026-02-25 投资要点 AI大模型：2025年，中国AI大模型产品形态进入成熟期，成为市场爆发的直接推动力，低成本、高性能 的技术基础形成了从底层支撑市场高速增长的关键条件，为MaaS和企业大模型的广泛应用创造了可持续 的商业化环境；多模态模型的快速迭代将AI应用从单一文本生成扩展至图像、视频、语音等复合场景，提 升了模型的可用性与商业化潜力；同时，各大厂商通过推出通用基座模型、行业专属模型及低门槛API服 务，构建了完整的产品矩阵，极大降低了企业和开发者的接入成本；企业对AI价值的认知日益成熟，数字 化和智能化转型需求持续增长，推动客户需求从概念验证阶段进入规模化生产阶段，企业对于大模型的调 用频次和覆盖场景不断增加，从而带动MaaS平台和AI大模型解决方案市场进入了"结构性放量"周期。 AI应用：toB端，AI Agent是大模型重要的商业落地形式，已在客服、代码开发、营销、数据分析、金 融服务等多行业、多场景实现服务落地 ...

Core Insights - The report from Zhonghang Securities highlights the ongoing integration of AI products and services in the healthcare sector, focusing on areas such as medical imaging, clinical decision support, precision medicine, health management, medical information technology, drug development, and medical robotics. AI is evolving from a "technical assistant" role to becoming a core driver of "value reshaping" and "efficiency revolution" in the medical industry, with its commercial value permeating from research to clinical, payment, and patient levels [1] International Developments - In the international arena, significant advancements are noted in AI medical imaging diagnostics and AI-assisted drug discovery. AI systems for abdominal CT multi-disease triage and fetal abnormal ultrasound imaging have received FDA approval, indicating a shift from single-disease assistance to comprehensive triage and decision support systems. Collaborations between pharmaceutical companies and AI tech firms are enhancing cancer early screening capabilities, potentially increasing cancer diagnosis rates and accessibility to treatment drugs. Additionally, AI imaging diagnostics for stroke have gained recognition at top academic conferences, reflecting the growing acceptance of AI technology in clinical and research communities [1] - In drug discovery, international pharmaceutical companies are partnering with AI tech firms to accelerate new drug development. The world's first fully AI-designed antibody drug, GB-0895, has entered Phase III clinical trials, marking a significant breakthrough from concept to clinical practice. Google has also launched two open-source AI models for medical applications, enhancing capabilities in multi-modal analysis and voice interaction [1] Domestic Developments - Domestically, the value of AI in early drug development is being clinically validated, with companies like InSilico Medicine receiving FDA approval for new drug applications via AI platforms. AI-assisted diagnosis is expanding into various medical scenarios, with recent approvals for AI software in cervical cell digital pathology and accelerated AI healthcare initiatives from leading in vitro diagnostic companies. The emergence of large AI models in China is also noteworthy, with local teams publishing evaluation standards in international journals, showcasing the competitive edge of Chinese medical AI models [2] - Significant advancements are being made in AI imaging, surgical robots, and brain-computer interfaces, with AI accelerating the development of medicine and drug research. Recent policies related to AI in healthcare are being actively discussed, focusing on the reliability and compliance of AI-assisted diagnosis and the use of medical data [2] Investment Opportunities - Key investment opportunities identified include: 1) AI drug development: companies like Crystal Technology, Hongbo Pharmaceutical, Chengdu XianDao, and InSilico Medicine 2) AI medical imaging and assisted diagnosis: companies such as United Imaging Healthcare and Wandong Medical 3) Medical information technology and smart hospitals: firms like Jiahe Meikang, Chuangye Huikang, Donghua Software, and Weining Health 4) Internet healthcare and health platforms: including JD Health, Alibaba Health, and Ping An Good Doctor 5) Precision medicine and AI-driven medical services: companies like Kingmed Diagnostics, Runda Medical, and Meinian Health 6) Technology/data platform enterprises: such as iFlytek Medical and Yidu Technology [4] AI Medical Core Themes - The core themes in AI healthcare investment revolve around addressing industry pain points. AI-assisted diagnosis enhances diagnostic efficiency and consistency, supporting grassroots healthcare with clear cost-reduction and efficiency benefits. In cancer early screening, companion diagnostics, and efficacy prediction, AI contributes to achieving precision medicine. The maturity of AI applications varies, with AI medical imaging evolving from single-disease assistance to multi-disease integration and comprehensive management. AI-assisted drug discovery is transitioning from early discovery to clinical validation, necessitating attention to platform technology validation and deep collaborations with top pharmaceutical companies [3] - The development of large medical AI models and multi-modal AI, capable of processing diverse medical data, is crucial. The focus should be on the accuracy of these models in specialized fields, their integration with existing hospital information systems, and their potential to build an ecosystem as foundational "medical intelligent agents" [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603108 证券简称：润达医疗 公告编号：临2026-016 上海润达医疗科技股份有限公司 股东及董高减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 大股东及董高持股的基本情况 截至本公告披露日：公司董事、高级管理人员刘辉持有上海润达医疗科技股份有限公司（以下简称"公 司"、"润达医疗"）股份共计31,528,771股，占公司总股本5.22%。公司股东朱文怡持有公司股份共计 28,839,409股，占公司总股本4.78%。 转债代码：113588 转债简称：润达转债 ● 减持计划的主要内容 公司股东朱文怡及刘辉拟在本公告之日起15个交易日后的三个月内通过大宗交易或集中竞价交易方式减 持股份。 ■ 股东后续减持公司股份将严格遵守相关法律法规执行。在本减持计划公告之日起至减持计划实施期间， 公司如发生派发红利、送红股、转增股本、增发新股或配股等除权、除息事项，上述减持股份数量将相 应进行调整。 ■ 上述减持主体存在一致行动 ...

| 1 | 华能水电 | 控股股东一致行动人增持股份及后续增持计划 | | --- | --- | --- | | 2 | 海螺水泥 | 控股股东海螺集团拟7亿元-14亿元增持公司股份 | | 3 | 开普云 | 拟以5000万元至1亿元回购公司股份 | | 4 | 中顺洁亲 | 拟回购6000万元-1.2亿元股份用于员工持股计划或股权激励 | | 5 | 元力股份 | 拟以5000万元至6000万元回购公司股份 | | | | 2.24上市公司盘后减持情况 | | 1 | 新柴股份 | 董事白洪法、石荣及总监张看拟减持股份 | | 2 | 润达医疗 | 股东朱文怡及刘辉拟合计减持不超2.99%股份 | | 3 | 世光电 | 黄事林雪峰拟减持不超0.9760%股份 | | ব | 福有控股 | 股东宋春静拟减持不超2.00%股份 | | 5 | 嘉泽新能 | 股东宁夏比泰减持计划期限届满 累计减持4436.18万股 | 据统计，2月24日，盘后华能水电、海螺水泥、开普云、中顺洁柔、元力股份披露增持情况。包括新柴 股份、润达医疗、亚世光电、福石控股、嘉泽新能在内的5家A股上市公司披露减持情况。 ...

据统计，2月24日，盘后华能水电、海螺水泥、开普云、中顺洁柔、元力股份披露增持情况。包括新柴 股份、润达医疗、亚世光电、福石控股、嘉泽新能在内的5家A股上市公司披露减持情况。 | | | 2.24上市公司盘后增持情况 | | --- | --- | --- | | 1 | 华能水电 | 控股股东一致行动人增持股份及后续增持计划 | | 2 | 海螺水泥 | 控股股东海螺集团拟7亿元-14亿元增持公司股份 | | 3 | 开普云 | 拟以5000万元至1亿元回购公司股份 | | র্ব | 中顺洁柔 | 拟回购6000万元-1.2亿元股份用于员工持股计划或股权激励 | | 5 | 元力股份 | 拟以5000万元至6000万元回购公司股份 | | | | 2.24上市公司盘后减持情况 | | 1 | 新柴股份 | 董事白洪法、石荣及总监张春拟减持股份 | | 2 | 润达医疗 | 股东朱文怡及刘辉拟合计减持不超2.99%股份 | | 3 | 亚世光电 | 董事林雪峰拟减持不超0.9760%股份 | | ব | 福伯控股 | 股东宋春静拟减持不超2.00%股份 | | ਦੇ | 嘉泽新能 | 股东宁夏比泰减持计划期 ...

具体来看，刘辉拟减持数量不超746万股，不超过公司总股本的1.24%；朱文怡拟减持数量不超过1054 万股，不超过公司总股本的1.75%。 北京商报讯（记者 丁宁）2月24日晚间，润达医疗（603108）发布公告称，公司股东朱文怡及刘辉拟在 公告之日起15个交易日后的三个月内通过大宗交易或集中竞价交易方式减持股份。 ...